Funding cuts for government and academic researchers led to weakened demand for tools for "cutting-edge proteomics and life science research," said Waters CEO Douglas Berthiaume during a conference call discussing the company's second-quarter results.

That, along with orders delayed in anticipation of the launch of Waters' new Synapt G2-S mass spectrometer at the American Society for Mass Spectrometry annual meeting in June, led to slowing demand in Q2 for the company's existing Synapt machines, Berthiaume said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.